Oda Y, Irie S, Inagaki M, Fukumoto M, Ueda I, Ohmoto E, Fujimoto S, Endo Y, Watanabe S, Lai M, Takahashi I, Kimura I, Ishii H, Sezaki T
Gan To Kagaku Ryoho. 1983 May;10(5):1313-9.
Sixteen patients with hematologic neoplasms were treated with Human Lymphoblastoid Interferon (HL-BI) derived from Namalwa cell line. They were 6 multiple myeloma, 8 acute leukemia and 2 malignant lymphoma patients. All patients were previously treated with anticancer agents except one case with multiple myeloma. HLBI, 3.0 X 10(6) IU/day, was daily administered by intramuscular injection at least for 4 weeks. Three of 6 multiple myeloma responded to HLBI with a decrease of more than 25% in serum myeloma protein level. A case with pleural effusion due to massive infiltration of myeloma cells treated with intrathoratic administration of HLBI, in whom complete disappearance of pleural effusion was recognized. On the other hand, no patients with acute leukemia and malignant lymphoma responded except one case with acute lymphocytic leukemia, in which bone marrow lymphoblasts decreased transiently. Fever episodes, 13 of 16 cases, were more frequently seen but were manageable. Transient leukocytopenia and thrombocytopenia were also observed in 4 and 7 of 8 cases, respectively. No anaphylactoid reaction was seen. Thus, HLBI was expected useful in the clinical management of multiple myeloma.
16例血液系统肿瘤患者接受了源自Namalwa细胞系的人淋巴母细胞干扰素（HL-BI）治疗。其中6例为多发性骨髓瘤患者，8例为急性白血病患者，2例为恶性淋巴瘤患者。除1例多发性骨髓瘤患者外，所有患者此前均接受过抗癌药物治疗。HLBI的剂量为3.0×10(6)IU/天，通过肌肉注射每日给药，至少持续4周。6例多发性骨髓瘤患者中有3例对HLBI有反应，血清骨髓瘤蛋白水平下降超过25%。1例因骨髓瘤细胞大量浸润导致胸腔积液的患者接受了胸腔内注射HLBI治疗，胸腔积液完全消失。另一方面，除1例急性淋巴细胞白血病患者骨髓淋巴母细胞短暂减少外，急性白血病和恶性淋巴瘤患者均无反应。16例患者中有13例出现发热，较为常见但可控制。8例患者中分别有4例和7例出现短暂性白细胞减少和血小板减少。未观察到类过敏反应。因此，HLBI有望在多发性骨髓瘤的临床治疗中发挥作用。
